Skip to main content

Solara Active Pharma Sciences Ltd

Stage 2 · Advancing · week 7Setup 5.4 ★ FairSolid +5.6

As of 16 Oct 2026, Solara Active Pharma Sciences is in Stage 2 — advancing, the uptrend phase, in week 7 (since 2 Sep 2026). It closed at ₹697, 7.4% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.0% of stocks are in Stage 2.

Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API)… More about the company

₹696.7
+7.38% today
₹3,362 Cr · Small cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dPharmaceuticals 49.6%-2.5 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

5.4 ★ Fair

Momentum

Steady

Edge

Solid +5.6

Setup-score rank among Stage 2 peers: #16 of 59 in Pharmaceuticals · #20 of 70 in Health Care

Is SOLARA early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
vs 52W High
-7.4%
₹425.6 lo₹752.6 hi
7.4% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 7
1w13w26w
Week 7 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
26.3%
200 DMA: ₹551.8 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
10.83x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -2.3% vs MA50 +11.0%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-2.1%
3M
+22.1%
6M
+41.7%
YTD
+21.6%
1Y
+17.2%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
This stock ranks #38 of 66 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
49.6%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #32 of 56 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-20 → 2026-10-16
S4 16w
S2 36w
S4 20w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 7w → S4 16w → S1 3w → S2 10w → S3 2w → S2 36w → S3 7w → S4 13w → S1 4w → S4 2w → S1 7w → S2 8w → S3 11w → S4 20w → S1 7w → S2 6w → S3 3w → S2 6w current
Total tracked: 169 weeks across 18 stage runs.
Scan Membership
Prop Scan
Latest: 2026-10-16
Breakout Watch
Latest: 2026-09-02
47 appearances in last 60 days. First seen: 2024-01-25.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S2
Wk 7 · Vol 10.83x
2026-10-15S2
Wk 6 · Vol 0.47x
2026-10-14S2
Wk 6 · Vol 0.21x
2026-10-13S2
Wk 6 · Vol 0.25x
2026-10-12S2
Wk 6 · Vol 0.69x
2026-10-09S2
Wk 6 · Vol 0.39x
2026-10-08S2
Wk 5 · Vol 0.33x
2026-10-07S2
Wk 5 · Vol 0.29x
2026-10-06S2
Wk 5 · Vol 0.37x
2026-10-05S2
Wk 5 · Vol 0.52x
2026-10-01S2
Wk 5 · Vol 0.43x
2026-09-30S2
Wk 4 · Vol 0.31x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹649
200 DMA
₹551.8
52W High
₹752.6
52W Low
₹425.6
5D Low
₹640.7
Resistance levels (recent highs)
20d High
₹752.6
60d High
₹752.6
120d High
₹752.6
250d High
₹752.6
Next resistance
+8.0%
to 20d High
ROE
-0.6%
Profit margin -0.5%
About this companyHealth Care· Pharmaceuticals

Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immune-suppressant, loop diuretic, NSAIDs, anti-hyperkalaemia, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical development, impurity synthesis, and regulatory support. In addition, the company exports its products. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.